Pharmacy

Opportunities to lower drug prices, as promised by President Trump’s American Patients First Blueprint, are picking up steam, some progressing more quickly than others.

How new research shows the importance of targeted drug therapies.

The first step to addressing opioid abuse for employers is to identify potential misuse and addiction.

Virtual care comes to the pharmacy chain.

Chronic pain patients on opioid therapy have limited access to primary care providers, which could lead to negative outcomes

Clinical trials hold great promise for advancing healthcare-but only if the right patients are found.

Why a new study that actively tracks patient quality-of-life could be a big advancement in clinical trials.

Where and how greater numbers of pharmacists are getting involved at health systems.

A look at recent developments in treatment and the cost implications of various autoimmune diseases.

How the digitalization of pharmacy is transforming patient care.

The current and future treatments for the $10 billion condition.

The tech giant and pharmaceutical manufacturer are hoping to develop new solutions together.

How the drug pricing bill could affect pharmacy benefit managers.

Why lowering drug costs can start with machine learning and better patient interaction.

The pharmacy chain is offering free testing in partnership with Greater than AIDS

With a record number of innovative drugs queued for FDA approval, managed healthcare executives have an eye toward innovative new products that tackle difficult conditions.

With a country-wide focus on reducing the cost of prescription drugs, managed healthcare executives make their forecasts concerning the future of list prices.

How the right benefit design can help increase patient engagement and adherence to key maintenance therapies.

The service is designed to help CVS Caremark PBM clients more easily contract, implement, and manage their choice of available and emerging third-party health and wellness benefit solutions.

The rare disease community struggles to balance care with costs.

While aggressive early intervention may be useful for diabetes patients, that intervention must be sustained.

These are the important policies to watch out for in 2019.

CMS introduced indication-based formularies as a voluntary tool for plans to implement in 2020.

Are accelerated approvals having as much impact as the FDA hopes?

A new study has revealing findings about the effects of front-end opioid prescribing for knee, hip, and shoulder joint replacement patients.